Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial - Shitara, K; Özgüroğlu, M; Bang, Y J; KEYNOTE-061 investigators (Lancet, 2018)
(10142):